Non-thermal atmospheric pressure plasmas for cancer treatment: Status, issues, and challenges - Archive ouverte HAL Accéder directement au contenu
Communication Dans Un Congrès Année : 2018

Non-thermal atmospheric pressure plasmas for cancer treatment: Status, issues, and challenges

Résumé

Intensive ongoing research in the field of anticancer treatment points the atmospheric non-thermal plasma (ANTP) as a new potential mean to attack tumors from a distinct innovative approach. The antitumor effect of ANTP has been now clearly shown not only in vitro on many different cell lines, but also in vivo on murine models with various cancer types (glioblastoma, melanoma, colon, pancreas, bladder, ovary) [1, 2] and recently on human in a case study on head and neck cancer[3]. Although the mechanisms being far from fully understood, the therapeutic effect is admitted. To date, the literature reports mainly induction of apoptosis, effect, which is not restricted to cancer cells, and probably mask other aspects of the ANTP induced processes for cancer therapy. Recent studies on a possible immunogenic induction by plasma treatment [4, 5], as it has been already shown for some other physical treatment such as PEF (Pulsed Electric Field), attracted a lot of attention. In addition, results obtained on breast carcinoma were in favor of a triggering effect and clearly indicate a tumor growth regulation [6]. Taking into consideration the recent vessel normalization based-cancer treatment, the ANTP effect should be further investigated in view of blood vessels structure and function (blood flow) as well as tumor hypoxia compensation to confirm a possible NTP-based adjuvant approach for cancer treatments. These results suggest new ways to consider the plasma and its therapeutic delivery in ANTP-based tumor therapy in combination or not with others therapies such as chemotherapy or radiotherapy. Recently, study reported in [3] led to reflections on non-sustainable tumor response. The loss of effectiveness under long-term plasma treatment of cancer tissue opens questions about plasma application and protocol. It must be considered that the treated area is morphologically and chemically changing over the time, from activated surrounding to more normal tissues that are less humid and bacteriologically cleaner. This aspect is particularly important for the development efficient systems and protocols in plasma cancer treatment but also for any other plasma therapeutically approaches. It induce a in real-time in situ control of plasma production and at longer term a protocol adaptation taking into account the biological target evolution. In the presentation, after a short introduction on the biomedical applications of plasmas, we will first make a survey of the developments in the field of plasma antitumor effect around the world. Then we will concentrate on issues and challenges in the domain with a special attention to the different problems linked to the plasma/target interaction, including treatments of tissues and liquids, leading to the development of plasma production and plasma application controls. References [1] Brulle L et al, PloSOne 7 e52653 (2012) [2] M. Laroussi, D. Graves, M. Keidar, IEEE TRPMS, 2, 85 (2018) [3] H.R. Metelmann et al, Clinical Plasma Medicine 9, 6 (2018) [4] V. Miller, A. Lin, A. Fridman, Plasma activation of the immune system - new approach for treating cancers, Proceedings of the 22nd International Symposium on Plasma Chemistry, Antwerp, Belgium. [5] V. Miller, A. Lin, A, A. Fridman, PCPP, 36 256 (2016) [6] G. Collet, L. Ridou, E. Robert, et al, “NTP Antitumor Soft Treatment: Evidence of a Triggering Effect?” in ICPM5 proceedings, Nara, Japan (2014)
Fichier non déposé

Dates et versions

hal-02933759 , version 1 (08-09-2020)

Identifiants

  • HAL Id : hal-02933759 , version 1

Citer

Jean-Michel Pouvesle, Robert Eric. Non-thermal atmospheric pressure plasmas for cancer treatment: Status, issues, and challenges. COPSA 2018, Ghent University, Nov 2018, Ypres, Belgium. ⟨hal-02933759⟩
25 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More